These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 34663921)

  • 41. The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I-Associated Peptides.
    Bedran G; Gasser HC; Weke K; Wang T; Bedran D; Laird A; Battail C; Zanzotto FM; Pesquita C; Axelson H; Rajan A; Harrison DJ; Palkowski A; Pawlik M; Parys M; O'Neill JR; Brennan PM; Symeonides SN; Goodlett DR; Litchfield K; Fahraeus R; Hupp TR; Kote S; Alfaro JA
    Cancer Immunol Res; 2023 Jun; 11(6):747-762. PubMed ID: 36961404
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multiplexed relative and absolute quantitative immunopeptidomics reveals MHC I repertoire alterations induced by CDK4/6 inhibition.
    Stopfer LE; Mesfin JM; Joughin BA; Lauffenburger DA; White FM
    Nat Commun; 2020 Jun; 11(1):2760. PubMed ID: 32488085
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use.
    Engelhard VH; Bullock TN; Colella TA; Mullins DW
    Cancer J; 2000 May; 6 Suppl 3():S272-80. PubMed ID: 10874498
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors.
    Marcu A; Schlosser A; Keupp A; Trautwein N; Johann P; Wölfl M; Lager J; Monoranu CM; Walz JS; Henkel LM; Krauß J; Ebinger M; Schuhmann M; Thomale UW; Pietsch T; Klinker E; Schlegel PG; Oyen F; Reisner Y; Rammensee HG; Eyrich M
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599019
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The MHC I immunopeptidome conveys to the cell surface an integrative view of cellular regulation.
    Caron E; Vincent K; Fortier MH; Laverdure JP; Bramoullé A; Hardy MP; Voisin G; Roux PP; Lemieux S; Thibault P; Perreault C
    Mol Syst Biol; 2011 Sep; 7():533. PubMed ID: 21952136
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
    Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
    Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Direct identification of major histocompatibility complex class I-bound tumor-associated peptide antigens of a renal carcinoma cell line by a novel mass spectrometric method.
    Flad T; Spengler B; Kalbacher H; Brossart P; Baier D; Kaufmann R; Bold P; Metzger S; Blüggel M; Meyer HE; Kurz B; Müller CA
    Cancer Res; 1998 Dec; 58(24):5803-11. PubMed ID: 9865739
    [TBL] [Abstract][Full Text] [Related]  

  • 48. TransLnc: a comprehensive resource for translatable lncRNAs extends immunopeptidome.
    Lv D; Chang Z; Cai Y; Li J; Wang L; Jiang Q; Xu K; Ding N; Li X; Xu J; Li Y
    Nucleic Acids Res; 2022 Jan; 50(D1):D413-D420. PubMed ID: 34570220
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Elucidating the immunological effects of 5-azacytidine treatment in patients with myelodysplastic syndrome and identifying new conditional ligands and T-cell epitopes of relevance in melanoma.
    Frøsig TM
    Dan Med J; 2015 Aug; 62(8):B5144. PubMed ID: 26239596
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy.
    Tcyganov EN; Sanseviero E; Marvel D; Beer T; Tang HY; Hembach P; Speicher DW; Zhang Q; Donthireddy LR; Mostafa A; Tsyganova S; Pisarev V; Laufer T; Ignatov D; Ferrone S; Meyer C; Maby-El Hajjami H; Speiser DE; Altiok S; Antonia S; Xu X; Xu W; Zheng C; Schuchter LM; Amaravadi RK; Mitchell TC; Karakousis GC; Yuan Z; Montaner LJ; Celis E; Gabrilovich DI
    Cancer Cell; 2022 Oct; 40(10):1173-1189.e6. PubMed ID: 36220073
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Current perspectives on mass spectrometry-based immunopeptidomics: the computational angle to tumor antigen discovery.
    Zhang B; Bassani-Sternberg M
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37899131
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predicting peptide presentation by major histocompatibility complex class I: an improved machine learning approach to the immunopeptidome.
    Boehm KM; Bhinder B; Raja VJ; Dephoure N; Elemento O
    BMC Bioinformatics; 2019 Jan; 20(1):7. PubMed ID: 30611210
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The biogenesis of the immunopeptidome.
    Admon A
    Semin Immunol; 2023 May; 67():101766. PubMed ID: 37141766
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
    Maeurer MJ; Gollin SM; Storkus WJ; Swaney W; Karbach J; Martin D; Castelli C; Salter R; Knuth A; Lotze MT
    Clin Cancer Res; 1996 Apr; 2(4):641-52. PubMed ID: 9816214
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of HLA class I-restricted tumor-associated antigens in adult T cell leukemia cells by mass spectrometric analysis.
    Kawahara M; Hori T; Matsubara Y; Okawa K; Uchiyama T
    Exp Hematol; 2006 Nov; 34(11):1496-504. PubMed ID: 17046569
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100.
    Lapointe R; Royal RE; Reeves ME; Altomare I; Robbins PF; Hwu P
    J Immunol; 2001 Oct; 167(8):4758-64. PubMed ID: 11591807
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy.
    Depontieu FR; Qian J; Zarling AL; McMiller TL; Salay TM; Norris A; English AM; Shabanowitz J; Engelhard VH; Hunt DF; Topalian SL
    Proc Natl Acad Sci U S A; 2009 Jul; 106(29):12073-8. PubMed ID: 19581576
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Upstream open reading frames regulate translation of cancer-associated transcripts and encode HLA-presented immunogenic tumor antigens.
    Nelde A; Flötotto L; Jürgens L; Szymik L; Hubert E; Bauer J; Schliemann C; Kessler T; Lenz G; Rammensee HG; Walz JS; Wethmar K
    Cell Mol Life Sci; 2022 Mar; 79(3):171. PubMed ID: 35239002
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evolutionary Pressure against MHC Class II Binding Cancer Mutations.
    Marty Pyke R; Thompson WK; Salem RM; Font-Burgada J; Zanetti M; Carter H
    Cell; 2018 Oct; 175(2):416-428.e13. PubMed ID: 30245014
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quantifying immune-based counterselection of somatic mutations.
    Yang F; Kim DK; Nakagawa H; Hayashi S; Imoto S; Stein L; Roth FP
    PLoS Genet; 2019 Jul; 15(7):e1008227. PubMed ID: 31344031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.